United States· US:10122-210_8b236f4c-7654-49fe-bca9-ab947b72a1fd
Myalept
A metreleptin product containing metreleptin, registered in United States by Chiesi USA, Inc.. The same ATC class is registered in 12 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Metreleptin is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AA07 (metreleptin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Metreleptin · ATC A16AA07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- METRELEPTIN
- Manufacturer
- Chiesi USA, Inc.
- Country
- United States (US)
- ATC code
- A16AA07
- ATC class
- Metreleptin
- Defined daily dose
- 5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1110122210021 VIAL, GLASS in 1 CARTON (10122-210-02) / 2.2 mL in 1 VIAL, GLASS
- ndc1110122-210-02
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
193 interactions on record for metreleptin.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metreleptin · interactions on record
193 records
- 1 severe
- 188 moderate
- 4 minor
Most severe, free to view
- RolapitantA04AD14moderate
- NaloxegolA06AH03moderate
- Insulin (human)A10AB01moderate
- Insulin lisproA10AB04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Metreleptin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMYALEPTAChiesi Farmaceutici S.p.A., Parma
- CanadaMYALEPTACHIESI FARMACEUTICI S.P.A.
- SpainMYALEPTA 11,3 MG POLVO PARA SOLUCION INYECTABLEChiesi Farmaceutici S.P.A.
- FinlandMyaleptaChiesi Farmaceutici S.p.A.
- FranceMYALEPTA 11,3 mg, poudre pour solution injectableCHIESI FARMACEUTICI
- United KingdomMyalepta 11.3mg powder for solution for injection vialsChiesi Ltd
- BelgiumMyalepta 11.3 mgChiesi Farmaceutici
- NorwayMyaleptaChiesi Farmaceutici S.p.a.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Myalepta
- Liechtenstein · Myalepta
- Norway · Myalepta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/83cb7f5b-3880-4f0d-b64b-073ad8db4c38 GET /v1/drugs/83cb7f5b-3880-4f0d-b64b-073ad8db4c38?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "11.3",
"substance": "METRELEPTIN",
"productndc": "10122-210",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/2.2mL",
"application_number": "BLA125390",
"marketing_category": "BLA"
}See everything about metreleptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.